Conditions
18 health conditions with evidence-based supplement research
Explore health conditions with evidence-graded supplement recommendations. Each condition page ranks ingredients by the strength of clinical research supporting them.
How We Grade Evidence
Each condition page ranks supplement ingredients by the strength of clinical evidence. Here is what each grade means:
Strong Evidence
Multiple randomized controlled trials (RCTs) or meta-analyses with consistent positive results and large sample sizes.
Good Evidence
At least one RCT with mostly consistent results across studies. Evidence suggests benefit but more research may be needed.
Some Evidence
Small studies or observational data with some positive signals. Promising but insufficient for strong recommendations.
Very Early Research
In vitro studies, case reports, or pilot studies only. Early-stage research that requires clinical validation.
Acute Diarrhea
1.7 billion cases of childhood diarrhea globally per year; 525,000 deaths
Antibiotic-Associated Diarrhea (AAD)
5-39% of antibiotic users; varies by antibiotic class
Bloating and Intestinal Gas
15-30% of general population report regular bloating; more common in IBS patients (>75%)
Chronic Constipation
15-20% of adults globally; increases with age; more common in women
Clostridioides difficile Infection (CDI)
500,000 infections/year in the US; 29,000 deaths
Crohn's Disease
~0.3% in Western countries; peak onset 15-35 years
Functional Dyspepsia
10-20% of the general population
Gastroesophageal Reflux Disease (GERD)
20-30% in Western populations; 5-10% in Asia
Gut Dysbiosis
Prevalence not precisely defined; associated with Western diet, antibiotic use, and numerous chronic diseases
Helicobacter pylori Infection
~50% of global population infected; higher in developing countries
Increased Intestinal Permeability (Leaky Gut)
Prevalence uncertain; measurable by lactulose/mannitol ratio test. Common in IBD, celiac disease, alcoholism
Inflammatory Bowel Disease (IBD) — General
~0.5% in Western countries; rising incidence in Asia and South America
Irritable Bowel Syndrome (IBS)
10-15% of global population; more common in women (2:1 ratio)
Lactose Intolerance
65-70% of global population (varies widely by ethnicity: 5% Northern European to 90% East Asian)
Peptic Ulcer Disease
5-10% lifetime prevalence; declining due to H. pylori treatment
Small Intestinal Bacterial Overgrowth (SIBO)
Estimated 6-15% in healthy population; up to 80% in IBS patients
Traveler's Diarrhea
30-70% of travelers to high-risk areas depending on destination
Ulcerative Colitis (UC)
~0.3% in Western countries; peak onset 15-30 years
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.